3 transcripts
SDGR
Earnings call transcript
NASDAQ
2024 Q2
31 Jul 24
that opportunities, such as the recently announced predictive toxicology project, position us for sustained growth in the coming years.
Software revenue in Q2
SDGR
Earnings call transcript
NASDAQ
2024 Q1
1 May 24
, our Wee1/Myt1 inhibitor.
Our preclinical data package demonstrated the SGR-3515 exhibited sustained tumor growth inhibition while maintaining
SDGR
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
lethality. In A427 non-small cell lung cancer preclinical models, SGR-3515 has shown sustained tumor growth inhibition, while maintaining a favorable safety
- Prev
- 1
- Next